Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
121.23
-0.96 (-0.79%)
Streaming Delayed Price
Updated: 9:36 AM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?
↗
October 28, 2025
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings.
Via
Benzinga
Topics
Economy
Why Incyte (INCY) Stock Is Trading Lower Today
October 28, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.
Via
StockStory
Earnings Scheduled For October 28, 2025
↗
October 28, 2025
Via
Benzinga
Exploring Incyte's Earnings Expectations
↗
October 27, 2025
Via
Benzinga
Incyte (INCY) Q3 2025 Earnings Call Transcript
↗
October 28, 2025
Incyte (INCY) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views
↗
October 28, 2025
The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit.
Via
Investor's Business Daily
Topics
Government
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates
↗
October 28, 2025
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance.
Via
Chartmill
Topics
Earnings
Incyte (NASDAQ:INCY) Reports Strong Q3
October 28, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share...
Via
StockStory
Topics
Artificial Intelligence
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
October 28, 2025
From
Incyte
Via
Business Wire
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
October 27, 2025
From
Incyte and Enable Injections
Via
Business Wire
What To Expect From Incyte’s (INCY) Q3 Earnings
October 26, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.
Via
StockStory
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
October 25, 2025
From
Incyte
Via
Business Wire
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis
↗
October 24, 2025
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.
Via
Benzinga
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals
↗
October 22, 2025
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity.
Via
Chartmill
These S&P500 stocks are gapping in today's session
↗
October 20, 2025
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.
Via
Chartmill
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
October 19, 2025
From
Incyte
Via
Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
October 16, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic...
Via
StockStory
Topics
Artificial Intelligence
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
↗
October 14, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
October 12, 2025
From
Incyte
Via
Business Wire
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
October 10, 2025
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the...
Via
MarketMinute
Topics
Economy
Intellectual Property
What 14 Analyst Ratings Have To Say About Incyte
↗
October 09, 2025
Via
Benzinga
Which S&P500 stocks are gapping on Wednesday?
↗
October 08, 2025
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index.
Via
Chartmill
Incyte to Report Third Quarter Financial Results
October 08, 2025
From
Incyte
Via
Business Wire
2 Reasons to Like INCY and 1 to Stay Skeptical
October 02, 2025
Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly...
Via
StockStory
Topics
Stocks
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
September 29, 2025
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...
Via
MarketMinute
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2025
From
Incyte
Via
Business Wire
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
September 23, 2025
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...
Via
MarketMinute
Topics
Intellectual Property
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
↗
September 23, 2025
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs.
Via
Benzinga
Topics
Stocks
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
September 22, 2025
From
Incyte
Via
Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
↗
September 19, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
